Novartis Gene Therapies - Company Profile
Powered by 
All the data and insights you need on Novartis Gene Therapies in one report.
$295
- Save hours of research time and resources with
our up-to-date Novartis Gene Therapies Strategy Report
- Understand Novartis Gene Therapies position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Novartis Gene Therapies Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Novartis Gene Therapies Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 28 Jun 2019 | Lorem |
| Solid Biosciences’ SGT-001 has high dose safety on watch though Phase I/II efficacy profile expected to be strong in DMD, experts say | 19 Mar 2018 | Hamish McDougall |
| AveXis' AVXS-101 gene therapy has experts upbeat for future Type I SMA trial safety profile, antibody response not an issue | 16 Nov 2016 | Hamish McDougall, Fiona Barry |
| AveXis’ gene therapy, AVXS-101, has experts generally optimistic regarding future motor skill improvements in pivotal Type 1 SMA trial | 16 Nov 2016 | Hamish McDougall, Fiona Barry |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer